BidaskClub downgraded shares of Vermillion (NASDAQ:VRML) from a strong-buy rating to a buy rating in a research report report published on Friday morning, BidAskClub reports.

Shares of VRML traded up $0.30 during midday trading on Friday, hitting $3.60. The company had a trading volume of 1,279,297 shares, compared to its average volume of 1,061,370. The company’s 50 day moving average price is $2.20 and its 200 day moving average price is $1.16. The stock has a market cap of $321.35 million, a price-to-earnings ratio of -21.18 and a beta of 3.47. Vermillion has a 52 week low of $0.35 and a 52 week high of $5.61. The company has a quick ratio of 2.49, a current ratio of 2.51 and a debt-to-equity ratio of 0.20.

Vermillion (NASDAQ:VRML) last released its earnings results on Thursday, March 26th. The company reported ($0.03) earnings per share for the quarter. Vermillion had a negative return on equity of 155.25% and a negative net margin of 307.31%. The company had revenue of $1.31 million during the quarter.

Several hedge funds and other institutional investors have recently bought and sold shares of VRML. Heritage Investors Management Corp boosted its holdings in shares of Vermillion by 100.6% in the 1st quarter. Heritage Investors Management Corp now owns 32,339 shares of the company’s stock valued at $27,000 after buying an additional 16,214 shares during the period. Trellus Management Company LLC acquired a new position in shares of Vermillion in the 4th quarter valued at about $39,000. Oxford Financial Group Ltd. acquired a new position in shares of Vermillion in the 1st quarter valued at about $59,000. Commonwealth Equity Services LLC boosted its holdings in shares of Vermillion by 147.2% in the 1st quarter. Commonwealth Equity Services LLC now owns 128,000 shares of the company’s stock valued at $106,000 after buying an additional 76,216 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of Vermillion by 8.7% in the 1st quarter. BlackRock Inc. now owns 138,249 shares of the company’s stock valued at $114,000 after buying an additional 11,084 shares during the period. 18.09% of the stock is owned by institutional investors and hedge funds.

About Vermillion

Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.

Featured Article: What is a good rate of return for a mutual fund?

Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.